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Paclitaxel (Taxol) is a potent anticancer drug with proven activity
against a number of human solid tumours, including ovarian and
breast, non-small-cell lung, and head and neck cancer (Huizing et
al, 1995a; Rowinsky et al, 1995). Because of its poor water solu-
bility the drug is formulated in a mixture of polyoxyethylene-
glycerol triricinoleate 35 (Cremophor EL) and dehydrated ethanol
USP (1:1, v/v; Taxol®). Prior to intravenous (i.v.) administration
the drug solution is diluted 5- to 20-fold with saline or 5%
dextrose. Patients receiving therapeutic dosages (e.g. 175 mg m–2)
of paclitaxel (Taxol) receive about 25 ml of Cremophor EL
solvent. The non-linear pharmacokinetic behaviour of paclitaxel in
patients has been well documented (Huizing et al, 1993;
Sonnichsen et al, 1994; Gianni et al, 1995; Kearns et al, 1995;
Huizing et al, 1997). Both a reduction in the clearance and an over
proportional increase in peak plasma concentration (Cmax) of pacli-
taxel are observed with increasing dosages indicative that both
drug elimination and distribution were affected. We have recently
shown that the non-linear pharmacokinetics of paclitaxel in mice
results from Cremophor EL exclusively, since linear plasma phar-
macokinetics occurred when the same dose levels of paclitaxel
were administered in a Cremophor EL free drug formulation
(Sparreboom et al, 1996b). In patients, administration of paclitaxel
in a Cremophor EL free formulation to test if the pharmacokinetics
becomes linear is not a feasible option. Indirectly, however, our
observations support the idea that Cremophor EL may also be
responsible for the non-linear pharmacokinetics in patients
provided that the plasma levels of Cremophor EL are in the same
range as those observed in mice.
In mice, the plasma concentrations of Cremophor EL as estab-
lished by high-performance liquid chromatography (HPLC)
ranged from 0.3 to 2.1% (Sparreboom et al, 1996b). Information
on the pharmacokinetics of Cremophor EL in patients is limited. A
previous paper using a bio-assay reported Cremophor EL levels up
to 0.2% (Webster et al, 1993; Rischin et al, 1996). However, our
preliminary information using the HPLC assay has revealed that
the Cremophor EL levels are much higher (Sparreboom et al,
1996b; Van Tellingen et al, 1996). To address the issue if
Cremophor EL can also be held responsible for the non-linear
pharmacokinetics in patients, we have established the pharmaco-
kinetic behaviour of this excipient in patients receiving 135 or
175 mg m–2 of paclitaxel (Taxol) by 3- or 24-h infusions. Because
we have previously suggested that alterations in the affinity of
paclitaxel toward plasma components might provide an explana-
tion for the nonlinear plasma pharmacokinetics (Sparreboom et al,
1996b), we have now used an in vitro equilibrium dialysis assay
and determination of paclitaxel in plasma ultrafiltrate to assess the
influence of Cremophor EL on plasma binding of paclitaxel.
PATIENTS AND METHODS
Patients
The patients included in this study received paclitaxel formulated in
Cremophor EL:Ethanol 1:1 (v/v) diluted in saline, which was given
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Summary The non-linear plasma pharmacokinetics of paclitaxel in patients has been well established, however, the exact underlying
mechanism remains to be elucidated. We have previously shown that the non-linear plasma pharmacokinetics of paclitaxel in mice results
from Cremophor EL. To investigate whether Cremophor EL also plays a role in the non-linear pharmacokinetics of paclitaxel in patients, we
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infusions (Cl175–3 h = 42.8 ± 24.9 ml h–1 m–2; Cl175–24 h = 79.7 ± 24.3; P = 0.035 and Cl135–3 h = 44.1 ± 21.8 ml h–1 m–1; Cl140–96 h = 211.8 ± 32.0;
P < 0.001). Consequently, the maximum plasma levels were much higher (0.62%) in the 3-h infusions than when using longer infusion
durations. By using an in vitro equilibrium assay and determination in plasma ultrafiltrate we have established that the fraction of unbound
paclitaxel in plasma is inversely related with the Cremophor EL level. Despite its relatively low molecular weight, no Cremophor EL was found
in the ultrafiltrate fraction. Our results strongly suggest that entrapment of paclitaxel in plasma by Cremophor EL, probably by inclusion in
micelles, is the cause of the apparent nonlinear plasma pharmacokinetics of paclitaxel. This mechanism of a (pseudo-)non-linearity contrasts
previous postulations about saturable distribution and elimination kinetics and means that we must re-evaluate previous assumptions on
pharmacokinetics–pharmacodynamics relationships.
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at a dose of 135 or 175 mg m–2 by 3-h infusion or at a dose of
175 mg m–2 in a 24-h infusion. Blood samples were collected by i.v.
sampling from the arm opposite to the arm used for the infusion.
This was performed in the 3-h infusion scheme before start, 1.5 h
after the start, at the end of the infusion and at 6, 18, 30,
60 min and 2, 4, 8, 12, 24, 30 and 48 h after the end of the infusion.
With the 24-h schedule the sampling was performed before the start,
3, 10 and 20 h after the start, at the end of the infusion and at 6, 18,
30, 60 min and 2, 4, 8, 12, 21, 30 and 48 h after the end of the infu-
sion. Four to eight patients were included in each arm. Four addi-
tional patients received paclitaxel by a 96-h infusion administered
through an IVAC i.v. administration set with low sorbing tubing
(IVAC Corp., San Diego, CA, USA) and an IVEX-II vented filterset
(0.22 mm; Millipore, Maksheim, France) was used for in-line filtra-
tion. Two patients received 140 mg m–2 and the two others with liver
metastases received 105 mg m–2. Blood sampling was done before
start, 8, 24, 48, 72 h after the start, at the end of the infusion and 2, 4,
10, 18 h after the end of the infusion. All patients had histologically
proven ovarian or breast cancer and gave written informed consent.
Further eligibility criteria included: (1) an Eastern Cooperative
Oncology Group (ECOG) performance status ≤ 2, (2) adequate
haematopoietic (absolute neutrophil count ³ 23109 l–1, platelet
count  ³ 1003109 l–1), hepatic (total bilirubin ≤ 1.25 times the upper
limit) and renal function (creatinine ≤ 1.5 times the upper limit), (3)
no prior chemotherapy within 4 weeks before study entry (or 6
weeks in case of mitomycin C, high-dose carboplatin or nitro-
soureas pretreatment) and (4) written informed consent. Dose prepa-
rations and premedication were standard and were described in
detail earlier (Huizing et al, 1993).
Cremophor EL determination
Cremophor EL levels in plasma have been quantified by an analyt-
ical method based on saponification of Cremophor EL, followed
by extraction with chloroform and derivatization of the released
fatty acid ricinoleic acid. The method has been described in detail
previously (Sparreboom et al, 1996a), however, minor modifica-
tions to the method have been implemented to improve the safety
of the assay and to reduce the chromatographic analysis time. In
short, volumes of 50 ml of plasma were mixed with 50 ml of
internal standard (2 mg ml–1 margaric acid in methanol) and 200 ml
of alcoholic potassium hydroxide USP. The samples were
centrifuged for 5 min at 3000 g and the supernatants were trans-
ferred into a clean vial and incubated at 80°C for 30 min. Next,
200 ml of 1 M hydrochloric acid and 1 ml of chloroform were
added and the vials were shaken vigorously for 10 min. After
centrifugation, the aqueous layer was discarded and the organic
fraction decanted into a clean glass tube and evaporated to dryness
under vacuum using a Speed-Vac Plus SC210A (Savant,
Faringdale, NY, USA) set at 43°C. The dried residues were
dissolved by vortex-mixing in 500 ml of chloroform containing
10% (v/v) of oxalyl chloride and, next, incubated at 70°C for
30 min to form the fatty acid acyl-chlorides. Next, the tubes were
dried by vacuum and 250 ml of 40 mM naphthyl amine in chloro-
form was rapidly added, followed by 50 ml of 5.6% (v/v) of
triethylamine in chloroform. After vortex-mixing, the tubes were
incubated at 37°C for 30 min, whereafter the organic solvent was
removed by vacuum. The residue was redissolved in 1 ml of
acetonitrile by sonication for 5 min. After adding 250 ml of water a
volume of 20 ml was subjected to chromatography using a stain-
less steel column (10 ´ 4.6 mm) packed with 3 mm Microspher C18
material kept at 40°C using a SPH-99 column oven (Spark,
Emmen, The Netherlands). The mobile phase comprised a mixture
of acetonitrile:10 mM potassium phosphate in water pH 7.0 (78:22;
v/v) and was delivered at a flow rate of 1.5 ml min–1. The column
effluent was monitored using a UV detector operating at 280 nm.
Peak height ratios of ricinoleic acid and internal standard were
used for quantitative computations. Calibration curves ranged
from 0.05% to 2.0% (v/v) of the plasma volume. The same proce-
dure, without the saponification step in alcoholic potassium
hydroxide, has been used to test the samples for the presence of
ricinoleic acid, liberated by in vitro or in vivo degradation.
Table 1 In vitro equilibrium dialysis assay.
Falcon tube Insert tube
Initial Equilibrium Initial Equilibrium
concentration concentration concentration concentration
Exp. 1 Cremophor EL (%, v/v) 0 ND 0 ND n = 3
Paclitaxel (ng/ml) 1000 527 ± 52 1000 621 ± 37
Exp. 2 Cremophor EL (%, v/v) 0 ND 0.5 ND n = 2
Paclitaxel (ng/ml) 1000 559 ± 20 1000 902 ± 6
Exp. 3 Cremophor EL (%, v/v) 0 ND 1.0 ND n = 3
Paclitaxel (ng/ml) 1000 505 ± 22 1000 1051 ± 33
Exp. 4 Cremophor EL (%, v/v) 0 ND 2.0 1.68 n = 3
Paclitaxel (ng/ml) 1000 493 ± 23 1000 1180 ± 77
Control 1 Cremophor EL (%, v/v) 0 ND 0 ND n = 4
Paclitaxel (ng/ml) 1000 474 ± 39 0 258 ± 35
Control 2 Cremophor EL (%, v/v) 2.0 1.88 ± 0.01 0 <0.05 n = 2
Paclitaxel (ng/ml) 1000 678 ± 18 0 <50
Control 3 Cremophor EL (%, v/v) 2.0 2.0 No insert tube n = 1
Paclitaxel (ng/ml) 1000 571
ND = not determined. Initial concentrations indicate nominal concentrations of Cremophor EL and paclitaxel at the start of the experiment. At equilibrium
(t = 64 h) the concentrations are measured; the results are given as equilibrium concentrations.332 O van Tellingen et al
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Pharmacokinetic analyses
Pharmacokinetic analyses were performed using non-compart-
mental methods. The elimination constant (k) was calculated by
linear regression of the final log-linear part of the concentration-
time curves. The area under the plasma concentration time curves
(AUC) was calculated using the linear trapezoidal rule from time =
0 until the last sampling point (Clast) and extrapolated to infinity
using the formula Clast/k. The apparent Clearance (Cl = Dose/AUC)
and the half-life (t1/2 = log 2/k) were estimated using classical equa-
tions. The area under the moment-time curve (AUMC) was also
calculated by the linear trapezoidal rule with extrapolation to
infinity ((Clast 3 tlast)/k + Clast/k2), with tlast being the time point
at which Clast was measured. The volume of distribution at
steady-state (Vdss) was calculated using the equation: Vdss = Dose
3AUMC/AUC2 – Dose 3 Infusion time/(2 · AUC) The unpaired
Student’s t-test was used for statistical analysis with the computer
program SPSS (version 6.1.3; SPSS Inc., Chicago, IL, USA). All
reported P-values are based on two-sided tests of significance.
In vitro equilibrium dialysis assay
All handlings were carried out under aseptic conditions in a laminar
flow hood. Blank human plasma (Central Laboratory for the Blood
Transfusion Services, Amsterdam, The Netherlands) was spiked
with 1000 ng ml–1 of paclitaxel (pure compound; Bristol-Myers
Squibb Company, Princeton, NJ, USA) by dilution from a stock
solution of 1 mg ml–1 in methanol. Aliquots of 2.0 ml were pipetted
into 15-ml polypropylene tubes (Falcon, Becton Dickinson
Labware, Franklin Lakes, NJ, USA). Two-side open glass tubes
(inside diameter: 8 mm) were fitted with a ZelluTrans Roth 2.0 V
(molecular weight cut-off: 2000 Dalton) dialysis membrane (Carl
Roth GmbH+Co, Karlsruhe, Germany) mounted on the bottom
side. The effective dialysis surface was about 50 mm2. Volumes of
300 ml of plasma were pipetted into these tubes, which were then
inserted into the Falcon tubes with the membrane fully immersed in
the plasma in the Falcon tube (Figure 1). The plasma in the insert
tube contained 0, 0.5, 1 or 2% of Cremophor EL and 1000 ng ml–1
of paclitaxel (Table 1: experiments 1–4 respectively). Insert tubes
with blank plasma were used as a control to monitor whether equi-
librium was reached. Insert tubes with blank human plasma placed
in Falcon tubes containing 2.0 ml of 1000 ng ml–1 of paclitaxel and
2% of Cremophor EL were used as control to check for passage of
Cremophor EL through the membrane. Falcon tubes containing
1000 ng ml–1 of paclitaxel and 2% of Cremophor EL, without insert
tubes, were used as control to check the stability of these
compounds during the incubation period. All tubes were incubated
at 37°C for 64 h. Next, the plasma from the insert tube and the
Falcon tube were separately stored until analysis. Paclitaxel levels
were analysed using an HPLC method described previously
(Huizing et al, 1995b).
Table 2 Pharmacokinetic parameters of Cremophor EL
Taxol Cremophor EL Patients Cmax AUC t1/2 CL Vdss
dose dose (%) (% h) (h) (ml h–1 m–2)  (l m–2)
mg m–2 -h-1 ml m–2
175–3 14.6 1 0.70 46.6 58.5 31.3 2.54
2 0.70 61.1 73.1 23.9 2.71
3 0.57 36.3 49.1 40.2 2.80
4 0.58 49.9 68.2 29.2 2.95
5 0.62 30.4 39.6 47.9 2.62
6 0.67 41.7 53.7 35.0 2.66
7 0.45 14.3 26.3 101.8 3.78
8 0.63 43.6 55.6 33.4 2.87
mean ± s.d. 0.62 ± 0.08 40.6 ± 14.0 53.0 ± 15.0 42.8 ± 24.9 2.87 ± 0.39
175–24 14.6 9 0.42 31.6 46.6 46.0 2.76
10 0.37 18.7 35.4 78.0 3.60
11 0.29 14.6 36.1 99.9 4.75
12 0.38 15.4 22.6 94.7 2.41
mean ± s.d. 0.37 ± 0.05 19.7 ± 7.8 35.2 ± 9.8 79.7 ± 24.3 3.38 ± 1.04
P = 0.059a P = 0.035a P = 0.40a
135–3 11.3 13 0.51 32.3 49.7 34.8 2.47
14 0.49 30.7 52.2 36.7 2.80
15 0.39 12.2 21.9 92.6 2.83
16 0.45 25.7 46.2 43.8 2.88
17 0.54 37.3 52.9 30.2 2.34
18 0.48 34.0 55.5 33.1 2.80
19 0.53 30.0 48.1 37.5 2.66
mean ± s.d. 0.48 ± 0.05 28.9 ± 8.1 46.6 ± 11.3 44.1 ± 21.8 2.68 ± 0.20
P = 0.38a P = 0.92a P = 0.29a
140–96 11.7 20 0.083 6.5 12.7 179.8 5.52
21 0.063 4.8 13.9 243.8 4.88
mean ± s.d. 13.3 ± 0.8 211.8 ± 32.0 5.20 ± 0.45
P = 0.005b P < 0.001b P < 0.001b
105–96 8.8 22 0.025 2.0 18.0 427.9 14.74
23 0.047 3.2 12.7 278.2 5.11
aStudent’s t-test relative to 175 mg m–2 –3 h schedule; bStudent’s t-test relative to 135 mg m–2 – 3 h schedule.Non-linear pharmacokinetics of paclitaxel 333
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Preparation of plasma ultrafiltrate
Blank human plasma was spiked with 5000 ng ml–1 of paclitaxel
and 0, 0.5, 1 or 2% (v/v) of Cremophor EL. Plasma ultrafiltrate
was prepared using Centrifree MPS-1 devices (Amicon, Danvers,
MA, USA), 5 per Cremophor EL level, and pooled to obtain suffi-
cient volume for analysis of paclitaxel and Cremophor EL.
RESULTS
When 175 mg m–2 of Taxol, corresponding to 14.6 ml m–2 of
Cremophor EL, was administered as 3-h infusion, the plasma
concentration of Cremophor EL reached a maximum (Cmax) of
0.62 ± 0.08% (v/v) of the plasma volume (Table 2 and Figure 2).
At the 135 mg m–2 dose level the peak level was proportionally
lower at 0.48 ± 0.05%. After cessation of the infusion, the plasma
levels started to decay without a clearly defined distribution phase.
There was a considerable inter-patient variability and no statisti-
cally significant differences in t1/2 and Cl were found between the
175 and 135 mg m–2 dose levels. However, a non-linear pharmaco-
kinetic behaviour of Cremophor EL became evident when we take
into account the results of the 24-h and 96-h infusion schedules.
The Cl of Cremophor EL increased almost twofold (P = 0.035)
when the same dose (175 mg m–2) of paclitaxel (Taxol) was given
at this eightfold lower dose rate. Moreover, the clearance increased
by fivefold (P < 0.001) if we compare the patient groups receiving
135 mg m–2 by 3-h infusion and 140 mg m–2 by 96-h infusion.
In all patients’ samples, the plasma levels of ricinoleic acid,
assayed by our Cremophor EL method with omission of the
saponification step in alcoholic potassium hydroxide, remained
below the lower limit of detection. Consequently, ‘free’ ricinoleic
acid which might have been liberated from Cremophor EL by in
vitro or in vivo degradation, was not present in plasma and did not
interfere with the accuracy of the Cremophor EL determination.
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Figure 2 The plasma concentration time profiles of Cremophor EL in
individual patients receiving paclitaxel as 3-h infusion at a dose of
175 mg m–2 (A) or 135 mg m–2 (B), as 24-h infusion at a dose of 175 mg m–2
(C) or as 96-h infusion (D) at a dose of 140 mg m–2 (solid lines) or 105 mg
m–2 (dotted lines).
Figure 1 Schematic setup of the in vitro equilibrium dialysis assay. Two
side open glass ‘insert’ tubes were fitted with dialysis membrane and
supplied with a volume of 300 ml of plasma. The tubes were inserted into a
Falcon tube containing 2.0 ml of plasma and placed at 37°C for 64 h334 O van Tellingen et al
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We have used an in vitro dialysis assay to study the impact of
Cremophor EL on the binding of paclitaxel to plasma components.
Given its low water solubility, the free paclitaxel levels in plasma
were considered to be too low to use the classical setup for dialysis
experiments using a protein-free acceptor buffer solution. The
current setup with plasma on both sides of the membrane mini-
mized the chances for losses due to absorption. Moreover, this
setup easily allowed to estimate the differential plasma affinity as a
function of increasing concentrations of Cremophor EL. Plasma
from the same subject was used at both sides of the membrane.
The dialysis membrane used in this study had a molecular weight
molecular cut-off (MWCO) of 2000, because it needed to block
the passage of Cremophor EL (approximate molecular weight =
3000) completely. However, as the molecular weight of paclitaxel
(854) is also close to the cut-off value, passage through the
membrane proceeds at a relatively low velocity and equilibrium
between the two compartments was not yet reached within the 64-
h incubation period (Control 1; Table 2). As can be seen from the
specimen, which does not contain an insert tube (Control 3), over
40% of the paclitaxel was degraded within this period. The degra-
dation by itself was not a problem, since we have analysed intact
drug by HPLC, but it impeded the use of the much longer incuba-
tion periods required for full equilibration. However, although the
current results may even somewhat underestimate the effect, it is
clear that the presence of Cremophor EL increased the concentra-
tion of paclitaxel within the insert tube in a concentration depen-
dent manner (Table 2). As expected, the Cremophor EL level at the
opposite side of the membrane in the control experiment was
below the lower limit of detection. However, in specimens
containing 2.0% of Cremophor EL about 10% was recovered as
ricinoleic acid, indicating (very slow) in vitro hydrolysis of
Cremophor EL. To further validate the results of the in vitro
dialysis assay we have also determined free paclitaxel by ultrafil-
tration. The free fraction of paclitaxel in plasma containing 0, 0.5,
1 and 2% (v/v) of Cremophor EL was 9.8%, 3.9%, 2.3% and 1.7%,
respectively, thus showing a Cremophor EL dependent decrease in
ultrafilterable paclitaxel. The concentration of Cremophor EL in
the ultrafiltrate fraction was below the detection limit of the assay.
DISCUSSION
This study shows that the plasma level of Cremophor EL after
intravenous infusion of Taxol is sufficient to cause the non-linear
plasma pharmacokinetics of paclitaxel in patients. Moreover, this
nonlinearity is in fact a pseudo-non-linear pharmacokinetic behav-
iour. Non-linear pharmacokinetic behaviour of cytotoxic drugs is
notorious, in particular because these drugs have a narrow thera-
peutic window and are usually administered at dosages close to the
tolerated maximum. True non-linear pharmacokinetic behaviour is
usually caused by saturation of drug elimination pathways (e.g.
metabolizing enzymes) and the higher drug levels in plasma are a
reflection of the higher amount of drug in the tissues. The non-
linearity of paclitaxel caused by Cremophor EL is different. Our
previous results in mice showed that the higher plasma level did
not reflect higher drug tissue levels. Increasing the dose by five-
fold from 2 to 10 mg kg–1 resulted in a 30-fold higher Cmax of pacli-
taxel in plasma, whereas the tissue levels increased more linear by
four- to sevenfold (Sparreboom et al, 1996b, 1996c). Based on this
result, we hypothesized that the equilibrium in drug levels between
plasma and tissues was shifted to plasma. Our in vitro equilibrium
dialysis assay and plasma ultrafiltrate experiments using human
plasma now clearly show that Cremophor EL, at clinically relevant
concentrations, increases the affinity of paclitaxel to plasma.
Consequently, the fraction of paclitaxel in plasma that is available
for distribution and elimination (‘free’ paclitaxel) is a function of
the Cremophor EL level. The nature of the interaction is not
known, however, it is likely that Cremophor EL is capable of
forming micelles, which can entrap paclitaxel. In aqueous solution
the critical micellar concentration (CMC) of Cremophor EL is
0.009% (Jonkman-de Vries et al, 1996), although the actual CMC
value in plasma may be higher due to the interference by other
macro molecules. Further evidence that micelles are being formed
results from the finding of very low levels of Cremophor EL in the
ultrafiltered plasma fraction. Given the high Cremophor EL levels
tested (up to 2%; v/v), it is very unlikely that all Cremophor EL is
bound to plasma proteins. Free Cremophor EL, however, would
have been able to freely pass the membrane (MW cut-off is 25
000). The absence of Cremophor EL in the ultrafiltrate indicates
that Cremophor EL forms complexes (micelles), which are too
large to pass the membrane. The finding of an increased affinity
towards plasma containing Cremophor EL, together with the more
or less linear increase in tissues observed in our study in mice,
suggest that the distribution and elimination of ‘free’ paclitaxel are
linear processes. The non-linear (e.g. more than proportional)
increase in plasma AUC with dose is due to the measurement of
‘total’ drug levels. It is pseudo-non-linear pharmacokinetic behav-
iour because it does not relate to higher drug levels in tissues and
will therefore not be accompanied by a corresponding more than
proportional increase in pharmacodynamic effects. In fact, the
higher affinity for plasma may lead to lower tissue levels as less
drug is available for tissue distribution. However, since the ratio of
the absolute amount of paclitaxel in tissues versus plasma is about
50:2 (viz. Vdss of paclitaxel (Sonnichsen et al, 1994) versus the
volume of plasma), even a large (e.g. two- or threefold) increase in
plasma levels will only have a minor effect on the tissue levels.
The concept of a Cremophor EL mediated increased affinity of
paclitaxel to plasma provides a more logical explanation for the
increasing Cmax of paclitaxel with increasing dose levels than the
postulated saturability of paclitaxel transport into the tissues,
which, although reported for other compounds previously (Gengo
et al, 1984), is a very rare phenomenon.
Our results also demonstrate that the Cl of Cremophor EL is
dependent on the dose-rate of the infusion. This nonlinear pharma-
cokinetic behaviour of Cremophor EL itself further augments the
effects on paclitaxel and explains why the non-linear pharmaco-
kinetics of paclitaxel is most evident when using short-term infu-
sion schedules. The non-linearity of Cremophor EL may be due to
the saturation of the enzyme(s) involved in its elimination. The
Vdss of Cremophor EL is very small and not (much) higher than the
volume of the blood compartment. Although the pathway of elim-
ination is currently unknown, it is possible that Cremophor EL
may be partly degraded in the blood compartment. Given the long
half-life such metabolic conversion in the blood occurs at a low
rate and saturation of this metabolic site might easily occur given
the high plasma levels. The two patients who demonstrated a
higher elimination (viz. Table 1: patient no. 7 and no. 15) may have
higher plasma concentrations of these metabolizing enzymes.
The non-linear pharmacokinetic behaviour of Cremophor EL, in
particular when administered at lower dose rates, may have further
consequences concerning the pharmacokinetics–pharmacody-
namics relationships of paclitaxel. It has previously been shown
that the toxic effect of paclitaxel (e.g. neutropenia) is correlated toNon-linear pharmacokinetics of paclitaxel 335
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the time at which the plasma levels of paclitaxel exceed 0.1 mM
(Huizing et al, 1993). A further study by Gianni et al (1995)
demonstrated that a threshold of 0.05 mM would be more appro-
priate. The latter study was initiated in part on the observation that
when paclitaxel was administered as long-term (96-h) i.v. infusion,
grade IV neutropenia was observed, although the threshold of
0.1 mM was not reached. The current work, however, shows that
the Cremophor EL levels should be taken into account when
making predictions based on paclitaxel plasma levels. The
Cremophor EL levels of patients receiving the 96-h infusions were
much lower than found in the 3- or 24-h schedules. As the effects
of entrapment of paclitaxel in the plasma compartment will be
less, the plasma levels of paclitaxel measured in the 96-h schedule
will represent a higher fraction of ‘free’ drug. Consequently, the
optimal value of the threshold level will vary with the schedule
used for drug administration. A higher fraction of ‘free’ paclitaxel
may also be anticipated when Taxol is given orally, since our study
to test the feasibility of oral Taxol, given in combination with
cyclosporin A, have shown that the plasma levels of Cremophor
EL remain well below the lower limit of detection of the assay
(Meerum Terwogt et al, 1998).
The plasma levels of Cremophor EL are substantially higher
than reported previously in a paper utilizing a bio-assay (Rischin
et al, 1996). This bio-assay is based on the property of Cremophor
EL to increase the accumulation of daunorubicin in a leukaemia
cell line (CEM/VLB100), which overexpresses the multidrug resis-
tance P-glycoprotein. The discrepancy between our chemical
assay and the bio-assay may be due to the fact that Cremophor EL
constitutes a relatively heterogenous group of polyoxyethylated
triglyceride compounds and the bio-assay only recognizes the
Cremophor EL fraction, which is responsible for the in vitro
modulation of P-glycoprotein activity. A more or less selective
clearance of this fraction would explain the lower levels observed
by Rischin et al (1996), however, other factors affecting the intra-
cellular daunorubicin accumulation cannot be excluded.
Our results are in line with those found using a colorimetric
assay for Cremophor EL described very recently (Sparreboom et
al, 1998a, 1998b). Although these authors studied the pharmaco-
kinetics over a wide dose range (100–225 mg m–2) using 3-h i.v.
infusions of paclitaxel (Taxol), they concluded linear pharmaco-
kinetic behaviour of Cremophor EL. However, their data does
suggest non-linear kinetics of Cremophor EL as a twofold increase
in the dose from 8.3 to 16.7 ml m–2 resulted in a threefold increase
in the AUC.
In conclusion, Cremophor EL is responsible for the non-linear
plasma pharmacokinetics in humans. However, it is a pseudo-non-
linearity, since Cremophor EL increases the affinity of paclitaxel
to plasma components in a dose-dependent manner and the
resulting higher total drug levels in plasma do not reflect higher
levels in tissues. Since the Cremophor EL levels depend strongly
on the schedule used for drug administration, the plasma levels of
Cremophor EL should be taken into account when making predic-
tions of pharmacokinetics–pharmacodynamics relationships based
on paclitaxel plasma levels.
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